tbuckley/cabot-search huggingface dataset:
Child of Mine
Authors: Stanley Cohen
Journal: Annals of Internal Medicine (2016)

Ad Libitum15 March 2016Child of MineStanley Cohen, MDStanley Cohen, MDFrom Atlanta, Georgia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-2109 Audio Reading - “Child of Mine” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Child of Mine," by S. Cohen. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail My sure hand stuttersin guiding you,shows insteadwho I'd rather not be,the person you could becomeI cry for my dysfluency,for your inheritance,when all you wantmay be timerather than promisesand their diffusion***I let my dreamsremain dreamsconceived at your birth Author, Article, and Disclosure InformationAffiliations: From Atlanta, Georgia.Current Author Address: Stanley Cohen, MD, Children's Center for Digestive Health Care, 993D Johnson Ferry Road, #440, Atlanta, GA 30342; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “Child of Mine” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Child of Mine," by S. Cohen. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 March 2016Volume 164, Issue 6Page: 424KeywordsBirthChild healthChildrenHealth care ePublished: 15 March 2016 Issue Published: 15 March 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation
Authors: Geun Hong, Kyung-Suk Suh, Suk-won Suh, Tae Yoo, Hyeyoung Kim, Min-Su Park, YoungRok Choi, Jin Chul Paeng, Nam-Joon Yi, Kwang-Woong Lee
Journal: Journal of Hepatology (2015)
Review of the Local Organizing Committee (LOC) medical services during the 12th FINA World Swimming Championships (25 m) in Doha, Qatar
Authors: H Paul Dijkstra, Liesel Geertsema, Nejib Benzarti, Elsbeth A L van Dorssen, Cees-Rein van den Hoogenband, Margo Mountjoy
Journal: British Journal of Sports Medicine (2016)

Background One of the primary roles of Fédération Internationale de Natation (FINA) is to promote athlete health. The planning and delivery of major international event medical services is carried out in collaboration with the Local Organizing Committee Medical Commission (LOCMC). Aspetar Orthopaedic and Sports Medicine Hospital provided the medical services to the 12th FINA World Swimming Championships (25 m) creating a unique opportunity for collaboration with FINA. Aim The purpose of this paper is to review the planning and delivery of medical services and athlete health promotion projects during the 12th FINA World Swimming Championships (25 m) to facilitate the planning of future sporting events of this size and scope. Methods The 12th FINA World Swimming Championships (25 m) hosted 974 athletes from 166 countries. The LOC medical team recorded all medical encounters—newly incurred (or acute exacerbations of chronic) injuries and illnesses as well as follow-up consultations. Results More than 90% of teams did not travel with a team physician and relied on the LOCMC for diagnosis and treatment of injuries and illnesses in athletes and accredited team officials. The LOC medical team had a total of 554 medical encounters: 385 therapy, 34 athlete injury, 65 athlete illness and 70 non-athlete encounters. Conclusions The LOCMC in collaboration with FINA delivered comprehensive medical services to athletes, officials and spectators attending the 12th FINA World Swimming Championships (25 m). This review paper provides information relevant to the planning and delivery of LOCMC medical services for future international swimming events contributing to the FINA objective of promoting athlete health.
Abstract 3529: KIM-1 is a novel therapeutic target in renal cell carcinoma
Authors: Venkata S. Sabbisetti
Journal: Cancer Research (2014)

Abstract Background. Renal cell carcinoma (RCC) is characterized by lack of early warning signs, diverse clinical manifestations, absence of a reliable diagnostic and predictive biomarker, and resistance to targeted therapy. Given the high incidence and worse prognosis, novel approaches for diagnosis, management and treatment of RCC are urgently needed. Kidney Injury Molecule-1 (KIM-1) is not expressed in normal kidney tissues but markedly up-regulated in dedifferentiated proximal tubular epithelial cells following renal injury. We demonstrated KIM-1 is expressed ubiquitoulsy by both primary and metastatic lesions of clear cell and papillary renal cell carcinoma, while barely detectable in other subtypes of RCC. The ectodomain of KIM-1 molecule cleaves by matrix metaloproteinases and sheds into surround milieu. In the present study, we investigated the role of KIM-1 in the pathogenesis of RCC. Methods. KIM-1 is stably transfected in immortalized tubular epithelial cells (LLC-PK1, gain-of-function) and KIM-1 was knockdown in RCC cell lines (loss-of-function) using lentiviral apporach and interoggated KIM-1 function in carcinogenesis. Results. Heterologous expression of KIM-1 increased cell proliferation, induced anchorage indepdent growth, increased migration and invasion potential, and increased the secreation of tumor promoting fractors, including TGF beta and IL-6 in immortalized tubular epithelial cells (PK1-KIM-1); while depletion of KIM-1 in RCC cells leads to cell cycle arrest at G1 phase and senescence. Recently, we and others have demonstrated that KIM-1 is a phosphatildyl serine receptor and the expression of KIM-1 converts a normal epithelial cell into a “semi professional phagocyte” and facilitates the removal of apoptotic and necrotic cells by recognizing phosphotidyl serine (PS) on their cell surface. Our data suggests that during this process, tumor epithelial cells undergo reprogramming and secrete and activate cytokines involved in cell survival and angiogenesis programs. Conclusions. The present study demonstrates that KIM-1-expression promotes tumorigenesis primarily by two distinct mechanisms: i) by directly conferring oncogenic properties to renal epithelial cells; ii) by resulting in production of a variety of chemokines and cytokines that support tumor progression and angiogenesis. We believe that our findings can significantly contribute to the development of novel therapeutic apporaches and in the advancement of management strategies in renal cell carcinoma and help reduce associated mortality and morbidity. Citation Format: Venkata S. Sabbisetti. KIM-1 is a novel therapeutic target in renal cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3529. doi:10.1158/1538-7445.AM2014-3529
Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial
Authors: P. Chinet-Charrot, F. Joly, H. Bourgeois, A. Lortholary, B. Leduc, F. Priou, I. Cumin, E. Sevin, K. Hamond, M. Henry-Amar
Journal: Journal of Clinical Oncology (2005)

5043 Background: A majority of advanced ovarian cancer relapse within one year after first line platinum-based chemotherapy. Methods: From March 2003 to October 2004, 97 patients who early relapsed (≤ 12 months) after platinum and taxane first line chemotherapy were enrolled in a phase II, multicenter study to evaluate the efficacy of the association of PD and IFO. The primary end point was objective response rate. Patients were stratified by treatment free interval (TFI) (< or ≥ 6 months). PLD (40 mg/m2, day 1) and IFO plus mesna (1700 mg/m2, continuous infusion, days 1–3), were given every 28 days, for 6 to 9 cycles. Response was assessed according to RECIST (measurable disease) or Rustin criteria (non measurable disease). Results: By November 2004, 84 patients were evaluable for response and toxicity. Initial characteristics were: median age 60 yrs (31 to 77), WHO PS≤1 96%, serous histology 79%, TFI<6 months 60%, measurable disease 46%. The median number of cycles was 4 (1 to 9). Chemotherapy was delayed because of toxicity in 10%. Among the 376 administered cycles, grade 3–4 anemia, thrombocytopenia and neutropenia occurred in 3%, 1% and 55%, respectively. Febrile neutropenia was observed in 6% of all the courses. Growth factors, erythropoietin, red blood cell and platelets transfusions were administered in 13%, 9%, 5% and 1% of courses. Other grade 3–4 toxicities were uncommon: nausea/vomiting 5%, hand-foot syndrom 1%, stomatitis 1%. One grade 3 encephalopathy was observed but no cardiologic toxicity. No toxic death was observed. The objective response rate (CR and PR) was 39%. Median overall survival was 8.4 months (1 to 43). Conclusions: IFO and PLD is a safe association. Our findings suggest a potential advantage of the addition of IFO to PLD compared to single agent therapy in patients who early failed first line chemotherapy for advanced ovarian cancer. No significant financial relationships to disclose.
Low prevalence of Chlamydia psittaci infection in French patients with ocular adnexal lymphomas (OAL)
Authors: D. Decaudin, A. Subtil, A. Ferreri, A. Vincent-Salomon, M. Ponzoni, L. Lumbroso-Le Rouic, R. Dendale, M. Escande, R. Dolcetti, P. De Cremoux
Journal: Journal of Clinical Oncology (2006)

17536 Background: A high prevalence of Chlamydia psittaci infection in both tumor tissues and peripheral blood mononuclear cells of Italian patients with OAL has been reported (Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell’Oro S, Fleischhauer K, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96(8):586–94.) This association has not been confirmed in some regions of the USA, and no data from other European countries are available. We therefore investigated the presence of DNA of C. psittaci, C. trachomatis, and C. pneumoniae DNA in French patients (pts) with OAL. Methods: Tumor samples from ophthalmologic biopsies of 16 OAL pts (10 conjunctiva, 6 orbit) were included in the study. Histologic type were MALT-type (n = 8), lymphoplasmocytic (n = 6), follicular (n = 1), and diffuse large B-cell (n = 1) lymphomas. Two other groups of lymphoproliferative disease were analyzed as controls. First, ten cases of nodal lymphomas (follicular and marginal zone B-cell lymphomas), and ten cases of reactive lymphoid hyperplasia were analyzed. A multiplex touchdown, enzyme time-release PCR designed to simultaneously detect C. psittaci, C. pneumoniae and C. trachomatis DNA sequences was performed. PCR analyses were performed in duplicate in an independent setting either inat the Curie Institut Curie in e, Paris, and in the National Cancer Institute, Aviano. Results: DNA of C. psittaci DNA was detected in the tumoral tissue of only one patient with follicular OAL. No DNA sequences of C. psittaci, C. pneumoniae and C. trachomatis DNA sequences were was detected in all any of the other OALs, or controls. Conclusions: The prevalence of C. psittaci infection in French pts with OAL was sensibly significantly lower than that reported in Italian series. Cross-controls between the two laboratories indicate that this finding is not due to different experimental conditions. Discrepancies may be explained by an heterogeneous epidemiological distribution of the bacterial infection. Large studies aimed to investigate geographical variations in the prevalence of this association are warranted. No significant financial relationships to disclose.
Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase <scp>II</scp> study
Authors: K. Reich, O. Graff, N. Mehta
Journal: British Journal of Dermatology (2016)

Palmoplantar pustulosis (PPP) is an inflammatory, debilitating skin disease. Topical drugs and systemic immunosuppressive agents are often ineffective. Previous uncontrolled studies have suggested that alitretinoin could be a meaningful treatment option for PPP.The primary objective was to determine response to alitretinoin for the treatment of PPP based on the Palmoplantar Pustulosis Area and Severity Index (PPPASI) after 24 weeks of treatment.A phase II, randomized, double-blind, placebo-controlled, multicentre study. Adult patients with PPP (with or without psoriasis) refractory to topical therapy and standard skin care were randomized 2:1 to alitretinoin 30 mg once daily or placebo for up to 24 weeks. The primary end point was PPPASI at week 24 (or the last visit in case of early withdrawal). Secondary end points included: percentage change from baseline in the modified Psoriasis Area and Severity Index (mPASI); percentage of patients with ≥ 50% or 75% improvement in PPPASI or mPASI scores from baseline; change in pustule count on the palms and soles; change in the Nail Psoriasis Severity Index and safety and tolerability assessments.Thirty-three patients were randomized: 24 patients to alitretinoin 30 mg and nine to placebo. Overall, there were no significant differences between alitretinoin 30 mg and placebo for any end point. The safety profile was consistent with that seen in patients with chronic severe hand eczema refractory to potent topical corticosteroids.Although the results were unexpected based on previous studies of alitretinoin in the treatment of PPP, this study provided no evidence to support further exploration of alitretinoin in the treatment of severe PPP.
miRNA profile and advanced stage endometrial cancer
Authors: K. E. Resnick, D. E. Cohn, I. Ivanov, C. Liu, C. Taccioli, C. M. Croce
Journal: Journal of Clinical Oncology (2008)

5561 Objective: To determine the miRNA profile for advanced versus early stage endometrial cancer Methods: 140 patients with primary stage I, III and IV endometrial cancer were identified from our database. RNA was extracted from the tumor samples using specified instructions. The integrity of the RNA was assessed using gel electrophoresis. The samples of RNA were arrayed onto a microchip using previously described methods. The microRNA (miRNA) microarray chip contains hundreds of human and mouse miRNA probes in triplicate. Hybridization was detected using a biotin binding to streptavidin-alexa complex. The identification of the miRNA signatures was performed using the quantile normalization method and leave-one-out method cross validation procedure. Results: The miRNA profile of stage I endometrial tumors was previously described. A profile was created that could differentiate between normal and tumor specimens with 90% accuracy. Twenty stage I tumors were subsequently re-analyzed on a later version of the Affymetrix chip and compared to 20 stage III/IV samples. A miRNA profile was identified that could correctly differentiate between early and advanced stage tumor with a mean value of 94.5% (SD=.02). Additionally, fourteen mirs were identified that showed greater than a 3-fold expansion or reduction in expression (p<.001). These miRNAs included the mir-125, let-7 and 26 families. When the advanced stage tumors were examined as a subset, mir-199a1 was significantly over- expressed in a subset of patients who demonstrated improved overall survival. Conclusion: We demonstrate that the miRNA profile can accurately predict early versus late stage tumors as well as a potential association of a single miRNA with improved outcome. Ideally, potential downstream targets of miRNAs over-expressed in advanced stage tumors would include putative tumor suppressor genes. Future experiments are needed to further delineate the molecular fingerprint of early versus advanced stage endometrial cancer. No significant financial relationships to disclose.
Cycle helmets
Authors: H. Jackson
Journal: BMJ (1999)

Editor—The Child Accident Prevention Trust was interested to read the report of the BMA’s Board of Education and Science on the compulsory use of cycle helmets.1 The trust agrees with the board’s recommendations, in that society is not yet ready to accept legislation in this area, and the other recommendations on the value of educational efforts to increase the use of cycling in general and of helmet wearing.

However, we would have liked to see more evidence of the effectiveness of helmets in reducing deaths and brain injury, which seems to be important in deciding to what extent helmets should be worn. In the report this is given a somewhat cursory review of just over one page, whereas standards and their verification, and the purchase and care of helmets, receive eight pages. The Child Accident Prevention Trust is the main organisation in Britian concerned solely with the reduction of accidents and injuries to children, but its work in this area and in particular its association with “Headstart” in the sale of low-cost helmets to schools—which has so far resulted in the sale of approximately 28 000 helmets—is not mentioned at all.

The report in the BMJ is also somewhat unbalanced in that in that it tends to take a negative approach to the problem.2 The statement that “a much greater number of lives would be saved if pedestrians and car occupants were encouraged to wear bicycle helmets” is sheer nonsense as it stands, without amplification and qualification.

The Child Accident Prevention Trust is strongly in favour of the promotion of cycling by children and of their use of helmets when doing so, both on the road and in off the road activities.
Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents
Authors: Lisette Okkels Jensen, Per Thayssen, Evald Høj Christiansen, Michael Maeng, Jan Ravkilde, Knud Nørregaard Hansen, Henrik Steen Hansen, Lars Krusell, Anne Kaltoft, Hans Henrik Tilsted, Klara Berencsi, Anders Junker, Jens Flensted Lassen
Journal: Journal of the American College of Cardiology (2016)
Quantitative Proteomic Analysis Reveals Maturation As a Mechanism Underlying Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia and PAX5 As a Re-Sensitising Therapeutic Target
Authors: Lindsay Nicholson, Caroline Evans, Elizabeth C Matheson, Lynne Minto, Christopher Keilty, Claire Schwab, Christine J Harrison, Andrew G. Hall, Christopher Redfern, Anthony Whetton, Julie Irving
Journal: Blood (2011)
Virus Containing Lymphocyte Cultures From Cancer Patients&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Erling M. Jensen, Wolodymyr Korol, Susan L. Dittmar, Theodore J. Medrek
Journal: JNCI Journal of the National Cancer Institute (1967)

Seven continuous cell cultures were established from 45 lymphoid tissue specimens from 43 cancer patients. All cultures were free-floating and appeared to be primarily lymphoblasts. Electron microscopic examination revealed herpesvirus-like particles in all the established cell lines and in one cell line that was maintained for only 1 month. The particles appeared identical to those observed in Burkitt's lymphoma and other lymphoma and leukemia cultures. In one instance virus particles were observed in the original tissue specimen before cultivation. The virus particles were not infectious for several cell lines known to be susceptible to herpes simplex virus and other members of this group.
China to train 22 000 more paediatricians in next four years
Authors: Michael Woodhead
Journal: BMJ (2016)

China is taking drastic steps to increase the number of paediatricians, as the country faces a crippling shortage of child health specialists with its move away from a one child policy.

The National Health and Family Planning Commission announced on 24 February that it would seek to expand training places to produce up to 22 000 extra paediatric physicians by 2020.

China is already experiencing a severe shortage of paediatricians, with fewer than 118 000 clinicians to serve a population of 220 million children under the age of 14, a ratio of only 0.5 practitioners per 1000 children.

The Chinese Medical Doctors Association stated that China needs an extra 200 000 paediatricians if it is to match the ratio of 1.4 paediatricians per 1000 patients seen in developed countries.

The shortage of paediatricians is likely to …
TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Authors: R. S. Herbst, D. Prager, R. Hermann, V. Miller, L. Fehrenbacher, P. Hoffman, B. Johnson, A. B. Sandler, R. Mass, D. H. Johnson
Journal: Journal of Clinical Oncology (2004)

7011 Background: Tarceva™ (erlotinib) is a potent reversible HER1/EGFR tyrosine kinase inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled study randomizing patients (pts) with previously untreated advanced (Stage IIIB / IV) NSCLC to receive erlotinib at 150 mg/d or placebo (PBO) with a course of 6 cycles of CP followed by maintenance monotherapy. Methods: Pts with performance status (PS) of 0 or 1 were eligible. Randomization was stratified by stage, >5% weight loss prior 6 months, measurable disease, and study site. The primary endpoint was overall survival (OS). Secondary endpoints included time to progression (TTP), objective response (OR), duration of response and time to symptomatic progression (TTSP; as determined by the Lung Cancer Symptom Scale). Sample size of 1050 was based on 80% power to detect a 25% benefit in OS, α=0.05. Results: 1059 pts were randomized / treated (526 erlotinib; 533 PBO). As shown in the table below, there was no difference in median OS for patients treated with erlotinib with CP over CP alone, and no difference in OR or in median TTP. TTSP results to be presented. PBO and erlotinib were equivalent in terms of overall adverse (99.5% erlotinib, 99.5% PBO) and serious adverse events (excepting rash and diarrhea; 47.7% erlotinib, 43.2% PBO). There was an imbalance in the SAEs attributed by the reporting investigator as leading to death (53 erlotinib; 27 PBO). Only 5 of the 80 fatal SAEs were partially related to study drug (i.e., causality was also related to concurrent therapy or underlying condition) by the reporting investigators. Conclusions: Erlotinib combined with carboplatin and paclitaxel chemotherapy did not confer a survival advantage over carboplatin and paclitaxel alone in pts with previously untreated advanced NSCLC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech AstraZeneca; Genentech Genentech